Astodrimer - Starpharma

Drug Profile

Astodrimer - Starpharma

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; BRI-7013; Fleurstat BV; SPL-7013; SPL7013 vaginal gel; VivaGel; VivaGel®BV

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomolecular Research Institute
  • Developer Starpharma
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein inhibitors; Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Bacterial vaginosis
  • Phase I/II Herpes simplex virus infections; HIV infections
  • Research Human papillomavirus infections; Zika virus infection

Most Recent Events

  • 21 Nov 2017 Preregistration for Bacterial vaginosis (Prevention) in USA (Vaginal)
  • 21 Nov 2017 Preregistration for Bacterial vaginosis in USA (Vaginal)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(Prevention, In volunteers) in Kenya (Vaginal, Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top